CD8A and cancer: When combined with antiPD-1, the results indicated durable antitumor responses by preventing the presentation of PD-1+/CD8+ T-cell infiltrates after drug withdrawal [187]; however, we should acknowledge the fact that the recently reported first-generation clinical trials using metformin in combination with systemic therapy have failed to significantly improve outcomes in cancer patients [188,189].